Skip to main content
. 2014 May 28;2014:203601. doi: 10.1155/2014/203601

Figure 2.

Figure 2

Specificity of 89Zr-trastuzumab for HER2-positive tumors. Coronal 89Zr-trastuzumab, 18F-FDG, and 18F-FLT PET images of athymic nude mice bearing subcutaneous HER2-positive NCI-N87 (left) and HER2-negative MKN-74 (right) are shown. ROIs (%ID/g) for 89Zr-trastuzumab, 18F-FDG, and 18F-FLT are indicated. +ve = positive; −ve = negative. This research was originally published in [3]. © by the Society of Nuclear Medicine and Molecular Imaging, Inc.